Cure for drug-resistant tuberculosis (DR-TB)

Context Recently, Johnson & Johnson’s patent expired on ‘Drug Bedaquiline- a medicine for drug-resistant TB’. This long-awaited expiry will allow generic manufacturers to supply the drug. Also, the Indian Patent Office rejected U.S. pharmaceutical giant Johnson & Johnson’s (J&J) attempt for Evergreening of Patent on manufacturing of the anti-tuberculosis drug Bedaquiline in India beyond July Read More